SarahAnneKremenMD

Staff Physician/Director of Behavioral Neurology Division, The Jona Goldrich Center for Alzheimer's and Memory Disorders, Cedars-Sinai Medical Center

Join to view full profile

Dr. Kremen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kremen's full profile

Already have an account?

Office
127 S. San Vicente Blvd
#A6600
Los Angeles, CA 90048
Phone+1 310-423-6472

Fax+1 310-423-0148

Summary

I am a board-certified behavioral neurologist with an interest in clinical care, clinical research, and public outreach and education. I see patients with neurodegenerative conditions, epilepsy, stroke, and other conditions that cause changes in language, memory, visual spatial, and frontal executive functioning. I am an experienced site PI for industry and academic clinical trials and observational studies of Alzheimer's disease. I also led the UCLA California Alzheimer's Disease Center for over 5 years. I am a member of the Medical Scientific Board of Alzheimer's Los Angeles.

Education & Training

VA Greater Los Angeles Healthcare SystemFellowship, Special Fellowship In Geriatric Neurology, 2009 - 2010
Greater Los Angeles HCSNeuropsychiatry and Behavioral Neurology, 2007 - 2009
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 2004 - 2007
UCLA-VA Greater Los AngelesInternship, Internal Medicine, 2003 - 2004
University of Maryland School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2004 - 2026
American Board of Psychiatry and Neurology Neurology
UCNSBehavioral Neurology and Neuropsychiatry

Clinical Trials

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease Start of enrollment: 2012 Oct 05
Terminated
Phase 1
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Start of enrollment: 2013 Nov 05
Terminated
Phase 3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease Start of enrollment: 2014 Dec 01
Completed
Phase 2
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Start of enrollment: 2015 Aug 13
Terminated
Phase 3
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study Start of enrollment: 2015 Sep 08
Completed
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). Start of enrollment: 2016 Mar 22
Terminated
Phase 3
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Start of enrollment: 2016 Oct 01
Recruiting
Nicotinamide as an Early Alzheimer's Disease Treatment Start of enrollment: 2017 Jul 12
Completed
Phase 2
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease Start of enrollment: 2019 Mar 27
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

30 citations
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
Jessica B Langbaum, Julie Zissimopoulos, Rhoda Au, Niranjan Bose, Chris J Edgar
Alzheimer's & Dementia. 2023-02-01
63 citations
Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.
John M. Ringman, Li-Jung Liang, Yan Zhou, Sitaram Vangala, Edmond Teng
Brain. 2015-04-01
69 citations
African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
Yan Zhou, David Elashoff, Sarah Kremen, Edmond Teng, Jason Karlawish
Alzheimer's & Dementia. 2017-01-01

Press Mentions

Beverly Hills Courier: Prevention and the Quest to Cure Alzheimer’s DiseaseOctober 9th, 2024
Cedars-Sinai Selected as Specialized Center of Care for Patients with Rare Movement DisordersOctober 2nd, 2024
Checking Your Health: Surprising Risk Factors That Play Role in Cognitive DeclineFebruary 9th, 2023
Join now to see all